Article Information
History
- August 13, 2021.
Article Versions
- You are currently viewing Version 1 of this article (August 13, 2021 - 11:37).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- David R. M. Smith1,2,3,*,#,
- Audrey Duval1,2,4,*,
- Jean Ralph Zahar4,5,
- Lulla Opatowski1,2,3,§ and
- Laura Temime3,6,§
- 1Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
- 2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France
- 3Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France
- 4IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France
- 5Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France
- 6PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France
- ↵# Corresponding author; email: davidrobertmundysmith{at}gmail.com
Posted August 13, 2021.
Rapid antigen testing as a reactive public health response to surges in SARS-CoV-2 outbreak risk in healthcare settings
